Language selection

Government of Canada

Search

Index of Published Newsletters

On this page

The Health Product InfoWatch

July 2019

June 2019

May 2019

April 2019

March 2019

February 2019

January 2019

December 2018

November 2018

October 2018

September 2018

August 2018

July 2018

June 2018

May 2018

April 2018

March 2018

February 2018

January 2018

December 2017

November 2017

October 2017

September 2017

August 2017

July 2017

June 2017

May 2017

April 2017

March 2017

February 2017

January 2017

December 2016

November 2016

October 2016

September 2016

August 2016

July 2016

June 2016

May 2016

April 2016

March 2016

February 2016

January 2016

December 2015

November 2015

October 2015

September 2015

August 2015

July 2015

June 2015

May 2015

April 2015

March 2015

February 2015

January 2015

Canadian Adverse Reaction Newsletters

October 1999;9(4)

  • Serious hematologic reactions associated with ticlopidine - update
  • Leukotriene receptor antagonists: suspected adverse reactions
  • Communiqué - Ropinirole (Requip): sleep disorder

July 1999; 9(3)

  • Alteplase (Activase rt-PA) for acute ischemic stroke
  • Abciximab (ReoPro): risk of acute thrombocytopenia
  • Nefazodone (Serzone) and hepatotoxicity
  • Communiqué - Amlodipine (Norvasc): hearing loss

April 1999; 9(2)

  • Bupropion (Zyban): suspected adverse reactions
  • 1998 ADR Statistics
  • Updates: immune globulin IV products, tolcapone (Tasmar)
  • Communiqué - Olanzapine (Zyprexa): priapism

January 1999; 9(1)

  • Isotretinoin and depression
  • Low-dose ASA and GI Bleeding
  • Guidelines for reporting ADRs
  • Communiqué - azithromycin, pentoxifylline, sertraline and carbamazepine: interaction

October 1998; 8(4)

  • Recent News About Drug Risks
  • New Ontario Regional ADR Centre
  • Discontinuation Reactions Associated With SSRIs
  • Communiqué - amantadine and warfarin, pantoprazole

July 1998; 8(3)

  • Quality Information in Spontaneous Reports
  • Donepezil: Suspected Adverse Reactions
  • Olanzapine: Hematological Reactions
  • Communiqué - valproic acid, cefaclor, latanoprost, protease inhibitors

April 1998; 8(2)

  • Alendronate-induced esophagitis
  • 1997 ADR statistics
  • Communiqué - dorzolamide hydrochloride, hydroxychloroquine sulfate, torvastatin calcium, risperidone, venlafaxine hydrochloride

January 1998; 8(1)

  • Drugs: QT interval prolongation and torsades de pointes
  • Ciprofloxacin use in epileptic patients taking phenytoin
  • Appetite suppressants - update
  • Communiqué - vigabatrin, mefloquine, lamotrigine

October 1997; 7(4)

  • Calcium-channel blockers
  • Azithromycin - severe iatrogenic hepatitis
  • Newsletter survey results
  • Communiqué - protease inhibitors, vigabatrin, terconazole, Fen-phen, heparin, paroxetine

July 1997; 7(3)

  • ACE inhibitors and bronchospasm
  • Interferon beta-1b
  • Radiopharmaceuticals
  • New Expert Advisory Committee on Pharmacovigilance

April 1997; 7(2)

  • Adverse drug reaction reporting - 1996
  • Potential abuse of butorphanol nasal spray
  • Aminoglycoside ear drops and ototoxicity

January 1997; 7(1)

  • Primary pulmonary hypertension and appetite suppressants
  • HIV protease inhibitors and increased bleeding in hemophilia?
  • Erythema multiforme and nifedipine
  • Congenital anomalies and fluconazole

October 1996; 6(4)

  • Cefaclor-associated serum sickness-like reaction
  • Newsletter Assessment - Questionnaire

July 1996; 6(3)

  • Cisapride: Arrhythmia Awareness
  • Midazolam: A Wake-Up Call
  • Clarithromycin: Tooth Discolouration and Smell Alteration

April 1996; 6(2)

  • Metformin: Lactic Acidosis
  • Nefazodone: ADR Profile
  • 1995 Statistics ADR or Product Fault?

January 1996; 6(1)

  • Cotrimoxazole
  • Nicotine Patches and exercise
  • Terbinafine - hepatobiliary reactions
  • SSRIs - hyponatremia

October 1995; 5(4)

  • Update: Fertility Drugs
  • Propofol: Convulsions
  • Contraindications: Dinoprostone
  • Vaginal Gel
  • DOCI List

July 1995; 5(3)

  • Reporting Adverse Drug Reactions
  • Lamotrigine (Lamictal): rashes
  • Drug Names: confusion from two fronts
  • Tiaprofenic Acid: cystitis
  • Ticlopidine: revisited
  • DOCI List

April 1995; 5(2)

  • Zidovudine: Benefits of use during pregnancy
  • Serevent®: Patient warnings must be stressed
  • Fluoroquinolones: Tendonitis
  • Topical Antifungals: Recent switch to over-the-counter
  • Phenazopyridine: Hemolytic anemia

January 1995; 5(1)

  • Risperidone and EPS Sumatriptan and migraine exacerbation
  • Bromocriptine
  • Fertility drug awareness
  • New regional centre for Quebec

October 1994; 4(3)

  • Regional Centres
  • New Drugs - Serzone, Neurontin, Sabril
  • Drugs of current interest

July 1994; 4(2)

  • Editorial Note
  • Terbinafine Herbal preparations

March 1994; 4(1)

  • Rhabdomyolysis and HMG-CoA
  • Reductase Inhibitors
  • Antidepressants and Suicide
  • Help Wanted: Risperdal

November 1993; 3(2)

  • Ticlopidine HCl - Hematological and Liver Effects
  • H1-Antihistamines - Cardiotoxic Effects

August 1993; 3(1)

  • ACE Inhibitors: Renal Effects
  • Sumatriptan Succinate: Chest Pain
  • Nicotine Patches: Update / Inadvertent Exposure

April 1992; 2(1)

  • ADR Program, 1991 Annual Report
  • Case Report: Drug Interactions with Omeprazole
  • Vasospasm with B-Blockers
  • GI Bleeding with Toradol®

August 1991; 1(2)

  • PPSP Workshop Minocycline - Case reports of severe liver and renal reactions
  • ADRs in the Elderly Ciprofloxacin - ADR profile Diclofenac - Hepatic reactions

January 1991; 1(1)

  • Saskatchewan ADR Pilot Project
  • The WHO Connection Working Group on ADR Assessment
Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: